HUANGSHAN-TOURISM
8.3.2024 03:41:31 CET | Business Wire | Press release
Incorporated tourism contents from not only Mount Huangshan itself, but also with attractions in its neighborhood, the Grand Huangshan region made its debut at ITB Berlin 2024, the world’s leading travel trade show with over 5,500 exhibitors from 170 countries and regions, which concluded in Berlin on Thursday.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240307230072/en/
Famous scenery such as pine trees, cloud seas, peculiarly-shaped stone peaks of Mount Huangshan in East China's Anhui province. (Photo: Business Wire)
Located in East China's Anhui province, Mount Huangshan, also known as the Yellow Mountain, is famous for its pine trees, cloud seas, peculiarly-shaped stone peaks, hot springs and winter snow scenery. With its natural and cultural values well interconnected, Huangshan was inscribed on the UNESCO World Cultural and Natural Heritage List in 1990.
This year marks the fifth consecutive participation of Huangshan Tourism Co., Ltd. (HSTD) in the ITB. Compared to the conventionally produced booths of previous years, HSTD innovatively designed its booth with the theme of the world-class leisure and wellness tourism destination, the Grand Huangshan region, this time.
They incorporated elements from tourist attractions, intangible cultural heritage skills, and traditional Huizhou cuisine of the four core cities in the Grand Huangshan region: Huangshan, Anqing, Chizhou, and Xuancheng. The booth featured a backdrop of traditional Chinese landscape paintings, adorned with simplified drawings of Huizhou-style architectural features, presenting a fresh image to exhibitors and visitors from around the world.
Meanwhile, a series of introduction material like visitor's guide and creative designed souvenirs have been distributed during the event. And the Grand Huangshan regional tourism resources, Huizhou cultural characteristics and high-quality international tourist routes were introduced at ITB as well, inviting international guests.
Many visitors expressed that they looked forward to having the opportunity to visit Huangshan and will introduce the beautiful scenery of Huangshan to more people.
According to HSTD, it’s already the second splendid appearance on the international stage for Huangshan, after the London Trafalgar Square Chinese New Year Celebration event early in February. It is also a significant step in implementing Huangshan City's global promotion plan for the urban brand "Creative Huangshan, Beauty in Huizhou."
In recent years, Huangshan Tourism has been dedicated to international exchange, cooperation, and brand promotion. It has actively participated in internationally influential cultural and tourism exchange events such as the New York Asian Cultural Festival, the United Nations "Journey Through Civilizations" photo exhibition, and the New York "Chinese Night."
Simultaneously, there has been a continuous increase in efforts to promote the brand worldwide, showcasing the tourism resources and cultural heritage of the beautiful Huangshan to overseas residents and tourists through multi-dimensional, comprehensive, and close-range approaches.
According to Huangshan, it will continue to spare no effort in showcasing the image of the Huangshan to international tourists in a fresh and compelling way and enhancing the visibility and influence of Grand Huangshan region as an international famous tourism destination.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307230072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
